← Back to Clinical Trials
Recruiting NCT05746442

NCT05746442 Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV/AIDS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05746442
Status Recruiting
Phase
Sponsor H. Lee Moffitt Cancer Center and Research Institute
Condition Smoking Cessation
Study Type INTERVENTIONAL
Enrollment 800 participants
Start Date 2023-01-11
Primary Completion 2027-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Smartphone-delivered Automated MessagingNicotine patchBrief Advice to Quit and Smoking Cessation Self Help Materials

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 800 participants in total. It began in 2023-01-11 with a primary completion date of 2027-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this research study is to test how well an automated text messaging smoking treatment program helps smokers with HIV quit smoking.

Eligibility Criteria

Inclusion Criteria: * 1\) being aged ≥18 years * 2\) being HIV-positive * 3\) self-reporting as a current combustible cigarette smoker (smoked ≥100 cigarettes in lifetime and currently smoke ≥1 cigarettes/day) * 4\) willing to set a date for a quit attempt within 2 weeks of study enrollment * 5\) being able to provide written informed consent to participate * 6\) being able to read Khmer (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form Exclusion Criteria: * 1\) history of a medical condition that precludes use of nicotine replacement therapy * 2\) physician/clinician deemed ineligible to participate based on medical or psychiatric condition * 3\) enrolled in another cessation program or use of other cessation medications.

Contact & Investigator

Central Contact

Sarah Jones

✉ Sarah.Jones@moffitt.org

📞 813-745-7525

Principal Investigator

Damon Vidrine, Dr.PH

PRINCIPAL INVESTIGATOR

Moffitt Cancer Center

Frequently Asked Questions

Who can join the NCT05746442 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05746442 currently recruiting?

Yes, NCT05746442 is actively recruiting participants. Contact the research team at Sarah.Jones@moffitt.org for enrollment information.

Where is the NCT05746442 trial being conducted?

This trial is being conducted at Phnom Penh, Cambodia, Phnom Penh, Cambodia, Phnom Penh, Cambodia.

Who is sponsoring the NCT05746442 clinical trial?

NCT05746442 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Damon Vidrine, Dr.PH at Moffitt Cancer Center. The trial plans to enroll 800 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology